Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study
| العنوان: | Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study |
|---|---|
| المؤلفون: | H. Jost Achenbach, Joachim H. Ficker, Wolfgang M. Brueckl, Wolfgang Schuette |
| المصدر: | BMC Cancer BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018) |
| بيانات النشر: | BioMed Central, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Oncology, Male, Cancer Research, Lung Neoplasms, Tyrosine kinase inhibitor, Kaplan-Meier Estimate, 0302 clinical medicine, Medizinische Fakultät, Surgical oncology, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, 030212 general & internal medicine, Epidermal growth factor receptor, Non-small-cell lung carcinoma, Molecular Targeted Therapy, Erlotinib Hydrochloride, Aged, 80 and over, biology, Age Factors, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ErbB Receptors, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Retreatment, Adenocarcinoma, Female, Erlotinib, medicine.drug, Research Article, medicine.medical_specialty, lcsh:RC254-282, 03 medical and health sciences, Internal medicine, Genetics, medicine, Humans, ddc:610, Lung cancer, Protein Kinase Inhibitors, Aged, Second line, business.industry, medicine.disease, respiratory tract diseases, Mutation, biology.protein, business |
| الوصف: | Background In this prospective non-interventional study, the effectiveness and tolerability of erlotinib in elderly patients with non-small-cell lung cancer (NSCLC) after ≥1 platinum-based chemotherapy were assessed. Methods A total of 385 patients ≥65 years of age with advanced NSCLC receiving erlotinib were observed over 12 months. The primary endpoint was the 1-year overall survival (OS) rate. Results Patients were predominantly Caucasian (99.2%), a mean of 73 years old; 24.7% had an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2. Most common tumor histologies were adenocarcinoma (64.9%) and squamous cell carcinoma (22.3%). Of 119 patients tested, 15.1% had an activating epidermal growth factor receptor gene (EGFR) mutation. The 1-year OS rate was 31% (95% CI 25–36) with a median OS of 7.1 months (95% CI 6.0–7.9). OS was significantly better in females than males (p = 0.0258) and in patients with an EGFR mutation compared to EGFR wild-type patients (p = 0.0004). OS was not affected by age (p = 0.3436) and ECOG PS (p = 0.5364). Patients with squamous NSCLC tended to live longer than patients with non-squamous EGFR wild-type tumors (median OS: 8.6 vs 5.5 months). Cough and dyspnea improved during the observation period. The erlotinib safety profile was comparable to that in previous studies with rash (45.2%) and diarrhea (22.6%) being the most frequently reported adverse events. Conclusions Erlotinib represents a suitable palliative treatment option in further therapy lines for elderly patients with advanced NSCLC. The results obtained under real-life conditions add to our understanding of the benefits and risks of erlotinib in routine clinical practice. Trial registration BfArM (https://www.bfarm.de; ML23023); ClinicalTrials.gov (NCT01535729; 20 Feb 2012). |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1471-2407 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::377e4d7235a79f506ae0cc9bd3e3443d http://europepmc.org/articles/PMC5870245 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....377e4d7235a79f506ae0cc9bd3e3443d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14712407 |
|---|